Floatz logo

Rivogenlecleucel

Hematologic Malignancies

Bellicum PharmaceuticalsCell therapyPhase 1Active
D
31/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
73/ 100

Competitive context

136 Active assets in the Hematologic Malignancies cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Gamida Cell ltd
Phase 3BB

View all 50 →

Same molecule, other indications

Rivogenlecleucel is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
44 / 100
View asset →
inborn error of immunityDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →